Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06PHS
|
|||
Drug Name |
EVT302
|
|||
Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1], [2] | |
Company |
Evotec Princeton, NJ
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Monoamine oxidase type B (MAO-B) | Target Info | Inhibitor | [1], [2] |
BioCyc | Superpathway of tryptophan utilization | |||
Tryptophan degradation via tryptamine | ||||
Dopamine degradation | ||||
Putrescine degradation III | ||||
Noradrenaline and adrenaline degradation | ||||
KEGG Pathway | Glycine, serine and threonine metabolism | |||
Arginine and proline metabolism | ||||
Histidine metabolism | ||||
Tyrosine metabolism | ||||
Phenylalanine metabolism | ||||
Tryptophan metabolism | ||||
Drug metabolism - cytochrome P450 | ||||
Metabolic pathways | ||||
Serotonergic synapse | ||||
Dopaminergic synapse | ||||
Cocaine addiction | ||||
Amphetamine addiction | ||||
Alcoholism | ||||
Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
5-Hydroxytryptamine degredation | ||||
Dopamine receptor mediated signaling pathway | ||||
Pathway Interaction Database | Alpha-synuclein signaling | |||
WikiPathways | Tryptophan metabolism | |||
Dopamine metabolism | ||||
Phase 1 - Functionalization of compounds |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.